Screener
ImmunityBio, Inc. IBRX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Change in fair value of warrant liabilities | 295,413 | 448 |
| Change in fair value of related-party convertible note | 236,625 | 42,582 |
| Non-cash interest expense related to revenue interest liability | 8,317 | 13,266 |
| Stock-based compensation expense | 8,169 | 9,537 |
| Write-off of convertible note receivable | 7,442 | — |
| Depreciation and amortization | 4,380 | 3,829 |
| Accretion of discounts on marketable debt securities, available-for-sale | (1,526) | (52) |
| Realized gain on instrument-specific credit risk | (1,425) | — |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s stock-based comp?
- ImmunityBio, Inc. (IBRX) reported stock-based comp of $8.17M in Q1 2026.
- How has ImmunityBio, Inc.'s stock-based comp changed year-over-year?
- ImmunityBio, Inc.'s stock-based comp decreased by 14.3% year-over-year, from $9.54M to $8.17M.
- What is the long-term trend for ImmunityBio, Inc.'s stock-based comp?
- Over 4 years (2021 to 2025), ImmunityBio, Inc.'s stock-based comp has grown at a -10.4% compound annual growth rate (CAGR), from $57.18M to $36.81M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about ImmunityBio, Inc.'s stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude